Europe — EMA
Nipfilan (Nintedanib)
Nintedanib, the active ingredient in Nipfilan, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is approved in the European Union for the treatment of idiopathic pulmonary fibrosis, systemic…
Request sourcing
What is Nintedanib?
Nintedanib, the active ingredient in Nipfilan, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is approved in the European Union for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and selected cases of non‑small cell lung cancer. The product complies with EU marketing authorisation standards and is manufactured under GMP conditions.
GNH USA supplies Nipfilan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, with a focus on quality and regulatory compliance.
What is Nintedanib used for?
Nintedanib is used to treat fibrotic lung disorders and certain lung cancers by targeting pathways that drive fibroblast activity and tumor angiogenesis.
- Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in forced vital capacity. -
